Page 34 - Read Online

gastric or gastro-oesophageal junction cancer (ToGA): a 63. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T,
phase 3, open-label, randomised controlled trial. Lancet Hainsworth J, Heim W, Berlin J, Baron A, Griffi ng S,
2010;376:687-97. Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R,
52. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Kabbinavar F. Bevacizumab plus irinotecan, fl uorouracil, and
Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, leucovorin for metastatic colorectal cancer. N Engl J Med
Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, 2004;350:2335-42.
Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, 64. Mayer RJ. Targeted therapy for advanced colorectal
Liepa AM, Gao L, Schwartz JD, Tabernero J. Ramucirumab cancer-more is not always better. N Engl J Med
monotherapy for previously treated advanced gastric or 2009;360:623-5.
gastro-oesophageal junction adenocarcinoma (REGARD): an 65. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J,
international, randomised, multicentre, placebo-controlled, Mayer RJ. Phase II trial of cetuximab in patients with
phase 3 trial. Lancet 2014;383:31-9. refractory colorectal cancer that expresses the epidermal
53. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, growth factor receptor. J Clin Oncol 2004;22:1201-8.
Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, 66. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS,
Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Ferrara N. Inhibition of vascular endothelial growth
Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. factor-induced angiogenesis suppresses tumour growth
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in vivo. Nature 1993;362:841-4.
in patients with previously treated advanced gastric or 67. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics
gastro-oesophageal junction adenocarcinoma (RAINBOW): of bevacizumab as monotherapy or in combination with
a double-blind, randomised phase 3 trial. Lancet Oncol cytotoxic therapy in preclinical studies. Cancer Res
2014;15:1224-35. 2005;65:671-80.
54. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, 68. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V,
Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Jeffery M, Schulz J, Richards D, Soufi -Mahjoubi R, Wang B,
Kang YK. Bevacizumab in combination with chemotherapy Barrueco J. Randomized, controlled trial of irinotecan plus
as fi rst-line therapy in advanced gastric cancer: a randomized, infusional, bolus, or oral fl uoropyrimidines in fi rst-line
double-blind, placebo-controlled phase III study. J Clin Oncol treatment of metastatic colorectal cancer: results from the
2011;29:3968-76. BICC-C Study. J Clin Oncol 2007;25:4779-86.
55. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, 69. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A,
Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L.
Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, XELOX vs FOLFOX-4 as fi rst-line therapy for metastatic
Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously colorectal cancer: NO16966 updated results. Br J Cancer
treated advanced gastric cancer: results of the randomized, 2011;105:58-64.
double-blind, phase III GRANITE-1 study. J Clin Oncol 70. Hochster HS, Hart LL, Ramanathan RK, Childs BH,
2013;31:3935-43. Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L,
56. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E. Safety and
Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, effi cacy of oxaliplatin and fl uoropyrimidine regimens with
Shah MA, Al-Batran SE. Prognosis of metastatic gastric and or without bevacizumab as fi rst-line treatment of metastatic
gastroesophageal junction cancer by HER2 status: a European colorectal cancer: results of the TREE Study. J Clin Oncol
and USA International collaborative analysis. Ann Oncol 2008;26:3523-9.
2012;23:2656-62. 71. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A,
57. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F,
Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination
Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufi an H, with oxaliplatin-based chemotherapy as fi rst-line therapy in
Rowinsky EK, Eckhardt SG. Phase I pharmacologic and metastatic colorectal cancer: a randomized phase III study.
biologic study of ramucirumab (IMC-1121B), a fully human J Clin Oncol 2008;26:2013-9.
immunoglobulin G1 monoclonal antibody targeting the 72. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ,
vascular endothelial growth factor receptor-2. J Clin Oncol Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L,
2010;28:780-7. Goldberg RM, O’Reilly S, Chu L, Azar CA, Lopa S,
58. Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib Wolmark N. Phase III trial assessing bevacizumab in stages
study of safety and pharmacokinetics of ramucirumab in II and III carcinoma of the colon: results of NSABP protocol
combination with Paclitaxel in patients with advanced gastric C-08. J Clin Oncol 2011;29:11-6.
adenocarcinomas. Oncologist 2015;20:493-4. 73. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J,
59. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Clarke S, Moore MJ, Cunningham D, Cartwright TH,
Global cancer statistics. CA Cancer J Clin 2011;61:69-90. Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R,
60. Wieser M, Sauerland S, Arnold D, Schmiegel W, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E,
Reinacher-Schick A. Peri-operative chemotherapy for the Makrutzki M, Shang A, Andre T, Hoff PM. Bevacizumab
treatment of resectable liver metastases from colorectal cancer: plus oxaliplatin-based chemotherapy as adjuvant treatment for
a systematic review and meta-analysis of randomized trials. colon cancer (AVANT): a phase 3 randomised controlled trial.
BMC Cancer 2010;10:309. Lancet Oncol 2012;13:1225-33.
61. Fearon ER, Vogelstein B. A genetic model for colorectal 74. Tabernero J. The role of VEGF and EGFR inhibition:
tumorigenesis. Cell 1990;61:759-67. implications for combining anti-VEGF and anti-EGFR agents.
62. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Mol Cancer Res 2007;5:203-20.
Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, 75. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang
Chau I, Van Cutsem E. Cetuximab monotherapy and Chien CR, Makhson A, D’Haens G, Pinter T, Lim R,
cetuximab plus irinotecan in irinotecan-refractory metastatic Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S,
colorectal cancer. N Engl J Med 2004;351:337-45. Schlichting M, Nippgen J, Rougier P. Cetuximab and
170 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦